Deep Value: cash covers more than 100% of the stock price

This company holds roughly $1M in cash and investments — more than its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

60 Degrees Pharmaceuticals

SXTP

Biotechnology · Healthcare

Price

$1.13

+0.00 (+0.00%)

Market Cap

$911,401

Exchange

NASDAQ Capital Market

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Good

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+2668.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 24K (2021) → 670K (2025)

Winston Score History

The full picture

60 Degrees Pharmaceuticals is a small specialty pharmaceutical company focused on treatments for infectious diseases, particularly those affecting military personnel and travelers. Its main product is Arakoda (tafenoquine), a once-weekly malaria prevention pill approved by the FDA. The U.S. Department of Defense is a key customer, and the company also targets civilian travelers heading to malaria-prone regions.

The company earns revenue by selling its prescription drug directly to government agencies and through retail pharmacies, though sales volumes remain very small. It operates primarily in the United States but targets markets wherever malaria is a travel risk. With a gross margin around 21% and a deeply negative operating margin, the company is spending far more than it earns, which is common for early-stage drug companies. The main growth driver is expanding Arakoda's adoption beyond the military into the broader travel medicine market, while the biggest risk is its limited cash runway and dependence on a single approved product.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+106.0% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

+82.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$2M/ year

↓ Declining (-58% vs prior year)

209.5% of revenue

11.6x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

3.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$1M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Strong grower

60 Degrees Pharmaceuticals is growing revenue at 106% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

27.3%

Modest — 27.3% gross margin

Profit after running costs

Operating Margin

-1092.4%

Losing money on operations — -1092.4%

Return on the money invested

ROCE

-340.5%

Weak — -340.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+68.0%

Fast-growing sales (+68.0% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-360.7%

Burning cash (-360.7%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial